Blood test could spare prostate cancer patients from harsh chemotherapy
Researchers are launching a major trial to determine whether a simple blood test for tumor DNA can personalize treatment for advanced prostate cancer, potentially letting some patients skip intense drugs while sparing them severe side effects. If successful, the approach could reshape how oncologists treat the disease and reduce healthcare costs associated with unnecessary toxicity.
Originaltitel: Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.
Prostate Biomarkers trial in metastatic hormone-sensitive prostate cancer (mHSPC) tests whether circulating tumor deoxyribonucleic acid (ctDNA) can personalize first-line treatment for mHSPC by safely de-escalating therapy in patients with undetectable ctDNA and by intensifying biomarker-matched treatment in ctDNA-detectable disease, aiming to preserve outcomes while reducing toxicity and improving quality of life.